Biosortia has opened the door to a new frontier of fascinating natural products and potential drug candidates by overcoming the challenges of accessing novel high quality bioactive compounds from uncultuable aquatic microorganisms.
Much of Nature's treasure trove of small molecules remains to be explored, particularly from the marine and microbial environments. David J. Newman, Ph.D.
Chief Natural Products Branch at NCI
Biosortia Pharmaceuticals aspires to become the premier, aquatic natural products company with a primary focus in drug discovery. We will accomplish this by leveraging our proprietary, state of the art technologies, deep research skills and relationships to become a leader in drug discovery. Our libraries will include those compounds previously unobtainable from the aquatic environment that are the unique, novel and rare. We will partner with the best Pharma players to help them materially advance their drug pipelines. Our libraries will include those compounds previously unobtainable from the aquatic environment that are the unique, novel and rare that have been proven active against various therapeutic area assays.
Biosortia has demonstrated an unprecedented ability to capture novel bioactive compounds from the aquatic environment at scale. These compounds and the resulting candidate compounds (Hits) represent a valuable source of drug leads. Biosortia further develops these chemically diverse compounds to create high quality libraries, to provide the pharmaceutical industry with quality candidate compounds.
With the majority of pharmaceuticals having been generated from natural products (secondary metabolites), access to such unique compounds is a great priority to the Pharma industry. The aquatic environment contains over 3.7 x 1030 microorganisms as well as the secondary metabolites they produce. Until now, bio-prospecting for the novel metabolites produced by these microorganisms has been very limited to impossible. This represents a new frontier for natural products drug discovery. Biosortia has developed the technology and systems to reach these highly valuable compounds that until now, were unrecoverable in quantities necessary for drug discovery and development.